OGN vs RNAZ · P/E 3.4, rev $3.02B vs $5.1M cap
Organon & Co (OGN) versus Transcode Therapeutics Inc (RNAZ) — a side-by-side from cached financials, not a winner call.
Organon & Co (OGN) is a drug manufacturers - general company listed on US.
Transcode Therapeutics Inc (RNAZ) is a biotechnology company listed on NASDAQ.
Latest reported OGN revenue for 2026-06-30 was $3.02B. Net income was $254.0M. OGN currently screens at market cap $2.52B and trailing P/E 3.4.
RNAZ does not have a complete income-statement cache yet.
OGN currently screens at market cap $2.52B and trailing P/E 3.4. RNAZ currently screens at market cap $5.1M.
Not investment advice. Open the OGN and RNAZ stock pages for the full models.
Not investment advice.